['diabetes', 'diabetes mellitus, type 2', 'cholesterolemia']
['bempedoic acid + ezetimibe fdc oral tablet', 'ezetimibe 10 mg oral tablet', 'placebo oral tablet', 'placebo oral capsule']

        Inclusion Criteria:

          -  Type 2 diabetes for 6 months or greater

          -  Currently taking stable diabetes medication for 3 months or greater

          -  HbA1c between 7-10%

          -  LDL-cholesterol greater than 70 mg/dL

          -  Women must not be pregnant, lactating, or planning to become pregnant within 30 days
             after last dose of study medication; and must be postmenopausal, surgically sterile,
             or willing to use 1 acceptable form of birth control during the study through 30 days
             after the last dose of study medication

        Exclusion Criteria:

          -  Body mass index > 40 kg/m2

          -  History of documented clinically significant cardiovascular disease

          -  Fasting triglycerides > 400 mg/dL

          -  History of Type 1 diabetes

          -  Uncontrolled hypothyroidism, liver dysfunction, renal dysfunction, gastrointestinal
             condition that may affect drug absorption, hematologic or coagulation disorder or
             active malignancy

          -  History of drug or alcohol abuse within 2 years
      